Chemkart India Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Chemkart India Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹248
Per ShareLot Size
600 Shares
Minimum Investment
₹1,48,800
Issue Size
₹80.08 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.22%
QIB Quota
49.66%
NII Quota
15.12%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Chemkart India Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Promoter Holding (Post-Issue)
73.31%
Issue Type
Book Building - SME
ISIN
INE0VWL01017
About the Company
We are a one stop destination for various nutritional, Health and sports supplement products, which are largely biased towards the food products providing health benefits in addition to their nutritional values, reflecting our ability in catering to nutritional as well as health needs of the end customers. Our company is based in Mumbai, offering diverse range of captivated nutritional supplements and components. We offer products across seven product categories, i.e. Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin. Thus, positioning us favorably to adapt to the growing awareness with respect to the needs of nutrition in the food products.
Industry Overview
This industry blends nutrition and pharmaceuticals, focusing on products that provide health benefits beyond basic nutrition. Our company mainly belongs to nutraceutical industry, specializes in a diverse array of captivating nutritional supplements and components designed to meet evolving health needs. We offer products across seven distinct categories: Glycine, Creatine Monohydrate 200Mesh, Inositol, L-Arginine, L-Glutamine, L-Carmitne, N-Acetyl L-Cysteine, Taurine, LGlutathione, Whey Protein Concentate. This comprehensive portfolio positions us strategically to respond to the increasing awareness and demand for nutritional solutions in food products. Our commitment to quality and innovation allows us to not only keep pace but also lead in meeting the dynamic nutritional needs of consumers, empowering them to achieve optimal health and wellness.
Company History
Our Company was incorporated on March 06, 2020 as "Chemkart India Private Limited", a private limited company under the Companies Act, 2013 pursuant to a certificate of incorporation dated March 06, 2020 issued by Deputy Registrar of Companies. Further, our Company was converted into a public limited company pursuant to a resolution passed by the Board of Directors in their meeting held on August 16, 2024 and by our Shareholders at an extra-ordinary general meeting held on August 16, 2024 and consequently the name of our Company was changed to `Chemkart India Limited' and a fresh certificate of incorporation dated October 04, 2024 was issued by Assistant Registrar of Companies/Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. The corporate identification number of our Company is U51220MH2020PLC338631.
Products & Services
- The Company is a one stop destination for various nutritional, Health and sports supplement products, which are largely biased towards the food products providing health benefits in addition to their nutritional values.
Growth Strategy
- Backward integrating our nutraceutical product business to capitalize on the global demand for nutraceutical products.
- Continue to focus on product innovation and design and further diversify our portfolio.
- Improve Debt - Equity Ratio.
- Leveraging our market skills and relationships.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of upto 32,29,200 equity shares of face value of Rs.10/- each (the "Equity Shares") of Chemkart India Limited ("The Company" or "Chemkart" or "the Issuer") at an offer price of Rs. 248 per equity share for cash, aggregating up to Rs. 80.08 crores comprising of fresh offer of up to 26,00,000 equity shares aggregating to Rs. 64.48 crores ("Fresh Offer") and an offer for sale of up to 6,29,200 equity shares by Ankit Shailesh Mehta and Parul Shailesh Mehta ("selling shareholders") aggregating to Rs. 15.60 crores ("offer for sale") ("public offer"). the offer includes a reservation of up to 1,66,200 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 248 per equity share for cash, aggregating Rs. 4.12 crores will be reserved for subscription by the market maker to the offer (the "market maker reservation portion"). the public offer less market maker reservation portion i.e. net offer of up to 30,63,000 equity shares of face value of Rs.10/- each, at an offer price of Rs. 248 per equity share for cash, aggregating up to Rs. 75.96 crores is herein after referred to as the "net offer". the public offer and net offer will constitute 26.69% and 25.32% respectively of the post offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Diversified product portfolio.
- In house processing and warehousing capabilities.
- Value proposition for Customers.
- Its business operations relies significantly on the continuous and timely supply of products from top 5 and top 10 suppliers, Also, the company does not have continuing and exclusive supply agreement with them. Any interruptions or discontinuation of same will adversely impact its overall performance and profitability.
- The company source its majority of the products from international market i.e. China. Any adverse developments affecting its procurement in this region could have an adverse impact on the company revenue and results of operations.
- We generate our majority of the sales from domestic market of which major portion of sales from our operations is generated from certain geographical regions especially, Maharashtra, Gujarat and New Delhi and minority portion of sales is from international market. Any adverse developments affecting our operations in these regions could have an adverse impact on our revenue and results of operations.
- Our Registered Office is not owned by us. In the event we lose such rights, our Business, Financial Condition and Results of Operations and Cash Flows could be adversely affected.
- The restated Consolidated financial statements have been provided by peer reviewed chartered accountants who is not statutory auditor of our Company.